Qiagen and Becton Dickinson (BD) have reached a settlement in a patent infringement lawsuit involving polymerase chain reaction (PCR) tests that Qiagen had acquired with its purchase of NeuMoDx Molecular.
The lawsuit had been filed in the U.S. District Court for the District of Delaware and involved the NeuMoDx 96 and NeuMoDx 288 clinical PCR systems that Qiagen acquired with its purchase of NeuMoDx in 2020.
Under the settlement deal, all pending patent and nonpatent claims have been resolved between BD and Qiagen and the codefendants, who were former officers of NeuMoDx.
Additionally, BD will receive a one-time, lump-sum payment of $53 million. The settlement includes general releases of all parties with no admissions of wrongdoing.